Phase 1/2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AntiPDL1 Monoclonal Antibody BGBA333 Alone and in Combination with AntiPD1 Monoclonal Antibody BGBA317 in Patients with Advanced Solid Tumors

  • Frentzas, Sophia (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusFinished
Effective start/end date20/12/18 → 3/07/20